Rt-pa - OmicsDI

Show results for

Unknown (968)
Transcriptomics (461)
Genomics (77)
Proteomics (36)
Metabolomics (10)
Genomic (1)

Organisms

Homo sapiens (185)
Mus musculus (100)
Arabidopsis thaliana (39)
Drosophila melanogaster (27)
Saccharomyces cerevisiae (20)
Rattus norvegicus (18)
Triticum aestivum (11)
Gallus gallus (9)
Colinus virginianus (8)
Bacillus amyloliquefaciens (7)
Apis mellifera (5)
Bos taurus (5)
Danio rerio (5)
Oncorhynchus nerka (4)
Candida albicans (4)
Vibrio parahaemolyticus RIMD 2210633 (3)
Bifidobacterium longum (3)
Anguilla anguilla (3)
Bombyx mori (3)
Pseudomonas putida (3)
Caenorhabditis elegans (3)
Cryptococcus neoformans (3)
Zea mays (3)
Salmo salar (2)
Oncorhynchus mykiss (2)
Enterococcus faecalis (2)
Sus scrofa (2)
Cereibacter sphaeroides (1)
Mayaro virus (1)
Streptococcus gordonii str. Challis (1)

Organisms

Homo sapiens (11)
Mus musculus (6)
Rattus norvegicus (4)
Glycine max (1)

Repository

biostudies-arrayexpress (479)
ENA (33)
pride (30)
EGA (19)
geo (12)
MetaboLights (10)
MassIVE (3)
dbGaP (1)
iProX (1)
jPOST (1)
PanoramaPublic (1)

Tissue

Bone marrow (3)
Cell culture (3)
Multipotent stem cell (3)
Blood clot (2)
Blood plasma (2)
Embryonic stem cell (2)
Hepatocyte (2)
Saliva (2)
Brain (1)
Epithelial cell (1)
Feces (1)
Heart (1)
Kidney (1)
Leaf (1)
Lung (1)
Neutrophil (1)
Oocyte (1)
Photosynthetic cell (1)
Plant cell (1)
Respiratory mucus (1)
Root (1)
Stem cell (1)
Tooth (1)
Venom (1)

Disease

Normal (7)
Ovarian tumor (2)
Cerebrovascular disease (2)
Oropharynx squamous-cell carcinoma in DiseaseLocation oropharynx has DiseaseStaging lymph node negative (N0) (1)
Not applicable (1)
Embryonic lethal at day 8.5 to 9.5 (1)
Insulin resistance (1)
Marsh 3 (1)
Small cell lung cancer (1)
Rheumatoid arthritis (1)
ARR1-SRDX (1)
Malignant Neoplasm (1)
Temporal lobe epilepsy (1)
Hypertensive (1)
5 days post MHV infection (1)
Neurofibromatosis type 1 (1)
Invasive ductal carcinoma (1)
Wilms tumour (1)
Alzheimer's disease (1)
COVID-19 (1)
Coronavirus infectious disease (1)
Pulmonary hypertension (1)
Wounds and Injuries (1)

Technology Type

Mass Spectrometry (30)
Shotgun proteomics (18)
Mass spectrometry (7)
Data-dependent acquisition (4)
NMR spectroscopy (2)
Bottom-up proteomics (2)
Data-independent acquisition (2)
Gel-based experiment (2)
AB SOLiD 4 System, Illumina HiSeq 2500, Illumina HiSeq 2000, AB SOLiD System 3.0 (1)
Mass spectrometry assay (1)
Affinity proteomics (1)
Affinity purification coupled with mass spectrometry proteomics (1)
Mass spectrometry imaging (1)
SRM/MRM (1)
SWATH MS (1)

Instrument Platform

G2565AA DNA microarray scanner [Agilent] (7)
NextSeq 500 (6)
Scanning hardware (4)
Illumina HiSeq 4000 (4)
ScanArray 5000 [PerkinElmer] (3)
ArrayWoRx Biochip Reader [Applied Precision] (3)
Liquid Chromatography MS - positive - reverse phase (3)
Axon- GenePix4000B (2)
Generation III Scanner (2)
NextSeq 550 (2)
Illumina NovaSeq 6000 (2)
Illumina HiSeq 2000 (2)
Illumina HiSeq 3000 (2)
Liquid Chromatography MS - negative - reverse phase (2)
Gentle MACS; BD FACS Aria III (1)
ICELL8 MultiSample NanoDispenser (1)
(Make:PerkinElmer,Model:ScanArray 4000XL) (1)
Axon GenePix 4000A scanning hardware (1)
428 [Affymetrix] (1)
BAS-5000 [FUJIFILM] (1)
G2565BA DNA microarray scanner [Agilent] (1)
ScanArray Express HT [PerkinElmer] (1)
GenePix 4000B [Axon Instruments] (1)
Ion Torrent Proton (1)
BGISEQ-500 (1)
Illumina MiSeq (1)
Illumina HiSeq 2500 (1)
LTQ Orbitrap Elite (1)
Q Exactive HF (1)
Q Exactive HF-X (1)

Publication Date

2010 (86)
2012 (51)
2014 (43)
2013 (42)
2011 (41)
2015 (34)
2005 (29)
2016 (28)
2008 (25)
2007 (24)
2006 (19)
2009 (18)
2023 (15)
2022 (14)
2024 (11)
2021 (11)
2018 (8)
2019 (7)
2004 (6)
2003 (6)
2025 (5)
2017 (5)
2020 (4)
2026 (4)

CHEBI ID

CHEBI:28044 (3)
CHEBI:15891 (3)
CHEBI:18012 (3)
CHEBI:18139 (2)
CHEBI:16933 (2)
CHEBI:28824 (2)
CHEBI:17992 (2)
CHEBI:16113 (2)
CHEBI:27693 (2)
CHEBI:27570 (2)
CHEBI:30751 (2)
CHEBI:17170 (2)
CHEBI:28300 (2)
CHEBI:16708 (2)
CHEBI:17724 (2)
CHEBI:506227 (2)
CHEBI:24898 (2)
CHEBI:25017 (2)
CHEBI:15428 (2)
CHEBI:15741 (2)
CHEBI:17497 (2)
CHEBI:16865 (2)
CHEBI:27266 (2)
CHEBI:17750 (2)
CHEBI:16449 (2)
CHEBI:29016 (2)
CHEBI:15318 (2)
CHEBI:15366 (2)
CHEBI:30887 (2)
CHEBI:16027 (2)

Metabolite Name

Taurine (4)
Fumaric acid (3)
Pyruvic acid (2)
Histidine (2)
Glycine (2)
AMP (2)
Dimethylamine (2)
Valine (2)
Succinic acid (2)
Malic acid (2)
Urocanic acid (2)
Phenylalanine (2)
Glutamine (2)
Glucose (2)
Creatinine (2)
Trimethylamine N-oxide (2)
Trihydroxy octadecenoic acid (TriHOME isomer II) (1)
Trihydroxy octadecenoic acid (TriHOME isomer I) (1)
Trihydroxy octadecadienoic acid (TriHODE isomer II) (1)
Dihydroxy eicosatetraenoic acid (DiHETE) (1)
Trihydroxy octadecadienoic acid (TriHODE isomer I) (1)
Alpha-Tomatine (1)
Acetyl tryptophan (1)
Feruloyl serotonin (1)
Indole acrylic acid (1)
Caffeoyl putrescine (1)
N,N-Dimethyglycine (1)
Indoxyl Sulfic acid (1)
2'.4'-DIHYDROXYACETOPHENONE (1)
Glutamic_acid (1)

First Public Date

2014 (6)
2025 (5)
2026 (4)
2024 (4)
2023 (3)
2019 (2)
2013 (2)
2022 (1)
2021 (1)
2020 (1)
2018 (1)
2017 (1)
2016 (1)
2015 (1)

Modification

4-tetrahydrothiazine-3-carboxylic acid (1)

Study type

Transcription profiling by array (344)
RNA-seq of non coding RNA (33)
RNA-seq of coding RNA (32)
ChIP-seq (20)
ChIP-chip by tiling array (11)
Other (6)
CUT&RUN (5)
Transcription profiling by RT-PCR (4)
Unknown experiment type (3)
RNAi profiling by array (2)
Methylation profiling by array (2)
Transcription profiling by SAGE (1)
Two-color microarray (1)
Human - One-color microarray (1)
Animal - High-throughput sequencing (1)
Transcription profiling by tiling array (1)
ChIP-chip by array (1)
Genotyping by array (1)
MicroRNA profiling by high throughput sequencing (1)
Comparative genomic hybridization by array (1)
RIP-seq (1)
Methylation profiling by high throughput sequencing (1)
RNA-seq of total RNA (1)

Release Date

2022 (107)
2010 (104)
2021 (96)
2025 (93)
2024 (90)
2020 (88)
2023 (86)
2014 (82)
2012 (79)
2016 (75)
2018 (73)
2015 (70)
2013 (68)
2011 (63)
2019 (57)
2017 (50)
2008 (40)
2009 (30)
2005 (30)
2007 (24)
2006 (19)
2026 (13)
2003 (6)
2004 (4)

Lab affiliation

BK21 FOUR Community-Based Intelligent Novel Drug Discovery Education Unit, College of Pharmacy and Research Institute of Pharmaceutical Sciences, Kyungpook National University, Daegu 41566, Republic of Korea (2)
Division of Cell Matrix Biology & Regenerative Medicine (L5) / Division of Cell Matrix Biology & Regenerative Medicine, University of Manchester (2)
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon, Portugal. (2)
Tianjin Medical University General Hospital (2)
Aalborg University Laboratory for Medical Massspectrometry (1)
C2VN, faculty of Medicine, Marseille (France) TIRO-MATOs, Faculty of Medicine, Nice (France) (1)
COI-NDM (University of Oxford) (1)
Center for Proteomics & Artificial Intelligence Center for Clinical Mass Spectrometry Allegheny Health Network Cancer Institute 100 S Jackson Ave., Pittsburgh, PA 15202 (1)
Center for Translational and Clinical Research, Department of Proteomics, School of Medicine, University of Zagreb, Zagreb, Croatia Drago Perović Department of Anatomy, School of Medicine, University of Zagreb, Zagreb, Croatia (1)
Department of Cardiology, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany (1)
Department of Chemistry, University of Wisconsin-Madison, United States (1)
Department of Developmental and Cell Biology, University of California, Irvine, Irvine, CA 92697, USA. (1)
Department of Ecogenomics and Systems Biology, University of Vienna, Vienna, Austria. (1)
Division of Cell Matrix Biology & Regenerative Medicine (L5) / Division of Cell Matrix Biology & Regenerative Medicine (1)
Friedrich-Loeffler-Institute (1)
ICAI-Indian Agricultural Research Institute, New Delhi, India (1)
Institute of Biotechnology, Czech Academy of Sciences, Prague-West, Czech Republic. (1)
Lab of Proteome Research, Department of Molecular Biology and Genetics, Federal Research and Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency, Moscow, Russia (1)
Laboratory of Proteomics, Internal Diseases Clinic, Faculty of Veterinary Medicine, University of Zagreb, Zagreb, Croatia (1)
Research Assistant Professor Laboratory of Cellular and Structural Biology The Rockefeller University, USA (1)
Sonja Hess, Dr. rer. nat. Director, Dynamic Omics AstraZeneca R&D Antibody Discovery and Protein Engineering One Medimmune Way, Gaithersburg, MD 20878 (1)
Stanford University, Department of Genetics, United States (1)
TIRO-MATOs, Faculté de Médecine, 28 Ave de Valombrose, 06107 Nice, France C2VN, Faculté de Médecine, Bd Jean Moulin, 13005 Marseille, France (1)
The Forsyth Institute (1)
University of Zagreb, Laboratory for proteomics, Internal diseases clinic, Zagreb (1)
ZBS6, Proteomics and Spectroscopy, Robert Koch-Institute, Germany, Berlin (1)

Previous page
1 / 156
You're on page 1
page 2
page 3
page 4
page 5
page ...
page 156
Next page

Sort by:

Relevance

Page size

Proteomic profiling comparison for plasma from patients with acute ischemic stroke under rt-PA treatment

In this study, a total of 10 patients who received rt-PA were enrolled. Plasma samples were collected before and 1 hour after the rt-PA infusion for proteomic analysis. Blood sample collection has been approved by Tianjin Medical University General Hospital Ethics Committee, and collection was condu...

ORGANISM(S): Homo sapiens (Human)

2024-07-12 | PXD046738 | Pride

Proteomic profiling comparison for plasma from patients with acute ischemic stroke under rt-PA treatment

ORGANISM(S): Homo sapiens (Human)

2024-07-12 | PXD046676 | Pride

Rt-pa Protein Acute ischemic stroke Plasam

Enhanced HRG production following rt-PA treatment modulate neutrophil immune activity and hemorrhagic transformation in ischemic stroke

PRJNA1037553 | ENA

Combination treatment with U0126 and rt-PA prevents adverse effects of the delayed rt-PA treatment after acute ischemic stroke.

Not available

S-EPMC8184783 | biostudies-literature

Does inhibiting Sur1 complement rt-PA in cerebral ischemia?

Not available

S-EPMC3507518 | biostudies-literature

Enhanced HRG production following rt-PA treatment modulate neutrophil immune activity and hemorrhagic transformation in ischemic stroke

Intravenous thrombolysis (IVT) with recombinate tissue plasminogen activatior (rt-PA) remains the primary approach for the treatment of acute ischemic stroke (AIS). Based on the short half-life of rt-PA, it is speculated that the coagulative/fibrinolytic cascade induced by alteplase administration m...

ORGANISM(S): Homo sapiens

2024-07-13 | GSE247434 | GEO

Intra-arterial administration of recombinant tissue-type plasminogen activator (rt-PA) causes more intracranial bleeding than does intravenous rt-PA in a transient rat middle cerebral artery occlusion model.

Not available

S-EPMC3184064 | biostudies-literature

Sex Differences in rt-PA Utilization at Hospitals Treating Stroke: The National Inpatient Sample.

Not available

S-EPMC5623663 | biostudies-literature

Does the sex of acute stroke patients influence the effectiveness of rt-PA?

Not available

S-EPMC3994292 | biostudies-literature

rt-PA with remote ischemic postconditioning for acute ischemic stroke.